Literature DB >> 18753335

Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia.

Hiroyuki Ochi1, Kazunari Kondo, Koji Matsumoto, Akinori Oki, Toshiharu Yasugi, Reiko Furuta, Yasuo Hirai, Hiroyuki Yoshikawa, Tadahito Kanda.   

Abstract

We have very limited information on serum neutralizing antibody in women naturally infected with the human papillomaviruses (HPVs) that are causally associated with cervical cancer. In this study, serum samples collected from 217 Japanese women with low-grade cervical intraepithelial neoplasia were examined for their neutralizing activities against HPV16, -18, -31, -52, and -58 pseudovirions. Eighty-four patients (39%), 35 patients (16%), 17 patients (8%), and 1 patient were positive for neutralizing antibodies against one, two, three, and four of these types, respectively. Presence of neutralizing antibody did not always correlate with detection of HPV DNA in cervical swabs collected at the time of blood collection. The neutralizing titers of the majority of sera, ranging between 40 and 640, were found to be conserved in the second sera, collected 24 months later, independently of emergence of HPV DNA in the second cervical swabs. The data strongly suggest that HPV infection induces anti-HPV neutralizing antibody at low levels, which are maintained for a long period of time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753335      PMCID: PMC2565939          DOI: 10.1128/CVI.00197-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.

Authors:  Kazunari Kondo; Yoshiyuki Ishii; Hiroyuki Ochi; Tamae Matsumoto; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  Virology       Date:  2006-09-28       Impact factor: 3.616

2.  Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age.

Authors:  Rachel L Winer; Qinghua Feng; James P Hughes; Mujun Yu; Nancy B Kiviat; Sandra O'Reilly; Laura A Koutsky
Journal:  Sex Transm Dis       Date:  2007-06       Impact factor: 2.830

3.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

Review 4.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

5.  Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease.

Authors:  Zizipho Z A Mbulawa; Anna-Lise Williamson; Debbie Stewart; Jo-Ann S Passmore; Lynette Denny; Bruce Allan; Dianne J Marais
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

6.  Arrangement of L2 within the papillomavirus capsid.

Authors:  Christopher B Buck; Naiqian Cheng; Cynthia D Thompson; Douglas R Lowy; Alasdair C Steven; John T Schiller; Benes L Trus
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

7.  Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

Authors:  Kazunari Kondo; Hiroyuki Ochi; Tamae Matsumoto; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327

8.  Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

Authors:  Judith F Smith; Michelle Brownlow; Martha Brown; Rose Kowalski; Mark T Esser; Wanda Ruiz; Eliav Barr; Darron R Brown; Janine T Bryan
Journal:  Hum Vaccin       Date:  2007-02-24

Review 9.  Molecular biology of human papillomavirus infection and cervical cancer.

Authors:  John Doorbar
Journal:  Clin Sci (Lond)       Date:  2006-05       Impact factor: 6.124

10.  Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix.

Authors:  Toshiyuki Maehama
Journal:  Infect Dis Obstet Gynecol       Date:  2005-06
View more
  6 in total

1.  Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.

Authors:  Brenda Y Hernandez; Thien Ton; Yurii B Shvetsov; Marc T Goodman; Xuemei Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

2.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

3.  Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.

Authors:  Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Debbie Edwards; Graham Munslow; Kate Soldan; Simon Beddows
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

4.  Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study.

Authors:  Xingmei Yao; Wen Chen; Chao Zhao; Lihui Wei; Yuemei Hu; Mingqiang Li; Zhijie Lin; Bizhen Lin; Xiaohui Liu; Ying Hong; Qing Li; Qinjing Pan; Xun Zhang; Mingzhu Li; Yuqian Zhao; Li Zhang; Huifang Xu; Fangfang Hu; Jun Zhao; Yue Huang; Wei Sheng; Ya Zheng; Shangying Hu; Yingying Su; Shoujie Huang; Huirong Pan; Fanghui Zhao; Youlin Qiao; Ting Wu; Jun Zhang; Ningshao Xia
Journal:  Lancet Reg Health West Pac       Date:  2021-07-16

5.  Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.

Authors:  Kei Kawana; Katsuyuki Adachi; Satoko Kojima; Shiro Kozuma; Tomoyuki Fujii
Journal:  Open Virol J       Date:  2012-12-28

6.  Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.

Authors:  Sara L Bissett; Giada Mattiuzzo; Eve Draper; Anna Godi; Dianna E Wilkinson; Philip Minor; Mark Page; Simon Beddows
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.